Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
Follow GH
Alert me
Guardant Health, Inc. (GH) P/S ratio
As of 5 November 2026, Guardant Health, Inc. (GH) trades at a P/S ratio of 16.2×. Over the past ten years it has ranged from 3.2× (April 2024) to 70.8× (June 2019); the current reading is higher than 56% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 13.0× | 157.00% |
| FY2024 | 5.1× | (3.61%) |
| FY2023 | 5.3× | (14.22%) |
| FY2022 | 6.1× | (77.37%) |
| FY2021 | 27.1× | (38.12%) |
| FY2020 | 43.8× | 32.72% |
| FY2019 | 33.0× | 161.90% |
| FY2018 | 12.6× | 114.42% |
| FY2017 | 5.9× | 0.00% |
| FY2016 | 5.9× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 18.7× | 11.27% |
| Jun 2026 | 16.8× | 50.10% |
| Mar 2026 | 11.2× | (13.92%) |
| Dec 2025 | 13.0× | 50.93% |
| 32 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| ICLR ICON PLC compare | 1.9× |
| LH Labcorp Holdings Inc. compare | 2.0× |
| DGX Quest Diagnostics Incorporated compare | 2.4× |
| CRL Charles River Laboratories International, Inc. compare | 3.8× |
| RVTY Revvity Inc. compare | 5.7× |
| MEDP Medpace Holdings, Inc. compare | 6.2× |
| ILMN Illumina, Inc. compare | 7.0× |
| MTD Mettler-Toledo International, Inc. compare | 8.2× |
| GH Guardant Health, Inc. | 16.2× |
| Diagnostics & Research industry median | 4.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on GH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement